This episode explores the game-changing role of diabetes medications in preventing heart failure and improving outcomes across cardiovascular, metabolic, and kidney systems. We review a meta-analysis on semaglutide, new insights on SGLT2 inhibitors, and the evolving concept of Cardiovascular-Kidney-Metabolic (CKM) syndrome — all with a focus on what this means for nephrology practice.

This week, we explore the evolving intersection of nephrology and urology—from advances in genitourinary cancer treatments to breakthroughs in benign prostatic hyperplasia management and neuromodulation. We discuss the trade-offs between survival and quality of life, highlight promising innovations like closed-loop systems and radiomics, and revisit the legacy of an early pioneer in integrative care.

Think you know kidney stones? Think again. In this deep dive, we unravel surprising new research connecting diet, genetics, and even bone health to stone formation. From silent symptoms in transplant patients to the role of claudin proteins in predicting risk, the future of kidney stone treatment is more personalized—and complex—than ever.

In this episode we explore how mitochondrial dysfunction drives kidney disease, the expanding role of SGLT2 inhibitors, and the systemic nature of CKD-related risks. We highlight breakthroughs in biomarkers, nanotechnology-based therapies, and new pediatric guidelines—revealing a shift toward precision and preventive nephrology.

This episode explores the evolving frontiers of nephrology, from early prediction of diabetes through urinary markers to the clinical challenges of CAR T-cell-related nephrotoxicity. We discuss advances in DMAND therapy, AI-based transplant monitoring, and the growing interplay between nephrology, cardiology, and infectious diseases. A focused look at how innovation is reshaping kidney care and multi-organ management.

In this episode of Inside Nephrology: A Weekly Review, we dive into cutting-edge advances in cellular therapy and precision medicine transforming autoimmune disease treatment. Highlights include promising CAR-T cell therapy in juvenile autoimmune conditions, the expanding role of SGLT2 inhibitors, gene-environment insights into serum urate regulation, microRNA impacts on secondary hyperparathyroidism, novel transplant rejection therapies, and encouraging results of avacopan in elderly patients with ANCA-associated vasculitis. Stay informed on these groundbreaking developments shaping the future of nephrology and patient care.